Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Amortization of Deferred Charges (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Amortization of Deferred Charges for 10 consecutive years, with $8850.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 29.98% to $8850.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $48359.0, a 333.33% increase, with the full-year FY2025 number at $52148.0, up 279.83% from a year prior.
  • Amortization of Deferred Charges was $8850.0 for Q4 2025 at Regen BioPharma, down from $34234.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $34234.0 in Q3 2025 to a low of -$42043.0 in Q3 2024.
  • A 5-year average of $6954.6 and a median of $4436.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: surged 5263.04% in 2022, then tumbled 4966.09% in 2024.
  • Regen BioPharma's Amortization of Deferred Charges stood at $22451.0 in 2021, then tumbled by 80.24% to $4436.0 in 2022, then dropped by 1.56% to $4367.0 in 2023, then skyrocketed by 189.42% to $12639.0 in 2024, then decreased by 29.98% to $8850.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Amortization of Deferred Charges are $8850.0 (Q4 2025), $34234.0 (Q3 2025), and -$7364.0 (Q2 2025).